Articles
The impact of the Iran-US conflict on the pharma and life sciences sector
08 Jul 2026The ongoing tensions between Iran and the United States have far-reaching consequences that extend beyond geopolitical boundaries. While the headlines often focus on energy markets and military strategies, the pharma and life sciences sector is also significantly impacted, with the conflict presenting a number of risks for companies operating in this space.
Injecting compliance: A tightening regulatory grip on GLP-1 medicines?
03 Jun 2026GLP-1s are currently dominating headlines. We consider whether a focused, tighter regulatory regime may be on the horizon.
Operation Pangea XVIII: What the UK’s largest medicines seizure means for the Pharma Sector
27 May 2026Over two million doses. £4.6 million. Just 14 days. The results from Operation Pangea XVIII are striking with important implications for businesses operating in the UK pharmaceutical supply chain.
Unlocking innovation for brain tumours
05 May 2026The Brain Tumour Charity has released a powerful report that highlights the urgent need for innovation in brain tumour treatments. Brain tumours remain the leading cancer killer of children and adults under 40, yet the pace of progress in developing new treatments has been alarmingly slow. The report identifies critical barriers to innovation and offers eight actionable recommendations to address these challenges.
The renewed Women's Health Strategy for England - a catalyst for change?
05 May 2026On 15 April 2026, the UK government published its renewed Women's Health Strategy ("Renewed Strategy") for the next 10 years. We explore what has been promised.
Manufacturing investment announcements paint exciting future for UK life sciences
20 Apr 2026Three pharma manufacturing investments of over £80 million have dramatically boosted UK life sciences prospects. They support the Life Sciences Sector Plan, which looks to make the UK the number one life sciences economy in Europe by 2030 and third in the world by 2035.
